All In Biotech

Free tool

FAERS Monitor: Choletec

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018963 or its brand name (Choletec, Technetium Tc-99m Mebrofenin Kit). Reports on generic versions are filed under their own applications.

Reports

92

Serious

31

34% of reports

Hospitalization

11

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug effect decreased34
  • multiple use of single-use product29
  • nausea10
  • hypersensitivity6
  • drug ineffective5
  • vomiting5
  • asthenia4
  • chills4
  • headache4
  • therapeutic response unexpected4
  • abdominal pain upper3
  • diarrhoea3
  • dizziness3
  • dysgeusia3
  • dyspnoea3

Reports by year received

View as table
YearReports
20042
20053
20062
20077
20082
20095
20102
201313
201433
20153
20162
20171
20184
20194
20201
20211
20232
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,067 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multiple use of single-use productSignal291187.0877.333,027
drug effect decreasedSignal34144.4110.64,708
therapeutic response unexpectedSignal420.47.856
dysgeusiaSignal39.23.015
chillsSignal47.83.017
hypersensitivitySignal67.43.427
abdominal pain upper33.31.13
nauseaSignal102.91.611
asthenia42.40.92
vomiting52.41.03
headache41.50.60
dizziness31.40.50
dyspnoea31.20.40
diarrhoea31.10.30
drug ineffective50.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.